News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Harbin Gloria Pharma In-licenses China Rights to Korean Drug



1/22/2014 8:07:23 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

by Richard Daverman, PhD

January 21, 2014 -- Harbin Gloria Pharmaceuticals in-licensed China rights to a hypertension treatment developed by Korea’s Boryung Pharma, paying $5.4 million upfront. Fimasartan, known as Kanarb, is a novel non-peptide angiotensin II receptor antagonist (ARB), which acts as a vasodilator. It has been marketed in Korea since 2011. As part of the deal, Gloria promised a minimum of $75 million in China sales over the next ten years. More details....

Help employers find you! Check out all the jobs and post your resume.

Read at ChinaBio Today


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES